The Milky Way: paediatric milk-based dispersible tablets prepared by direct compression - a proof-of-concept study

Samuel E F Orubu1, Nicholas J Hobson1, Abdul W Basit1

  • 1University College London School of Pharmacy, 29 - 39 Brunswick Square, London, WC1N 1AX, UK.

Insights

Milk-based dispersible tablets can improve paediatric formulation acceptability. Formulations with up to 30% milk content, when compressed appropriately, disintegrate quickly for easy administration to children.

Area of Science:

  • Pharmaceutical Sciences
  • Paediatric Drug Delivery

Background:

  • The World Health Organization recommends dispersible tablets as the preferred paediatric formulation.
  • Improving the acceptability of oral medications for children is a significant challenge in paediatric pharmacotherapy.

Purpose of the Study:

  • To investigate the potential of milk-based dispersible tablets as an acceptable paediatric formulation.
  • To explore the impact of milk content and compression force on tablet properties.

Main Methods:

  • Formulation of milk-based dispersible tablets using various milk powders and infant formulae.
  • Design-of-experiments approach to study the influence of milk type and content on tablet friability, crushing strength, and disintegration time.
  • Compaction simulation to assess the effect of compression force on tablet properties.

Main Results:

  • Increased milk content led to longer disintegration times.
  • Compression force significantly influenced the disintegration time of the model formulation.
  • Milk content and compression force were identified as key determinants of tablet disintegration.

Conclusions:

  • Up to 30% milk can be incorporated into 200 mg, 10-mm flat-faced placebo tablets via direct compression.
  • These tablets disintegrate within 3 minutes in a realistic volume of water (5-10 ml) for paediatric administration.
  • The milk-based platform can accommodate up to 30% of an active pharmaceutical ingredient, such as caffeine citrate.
Abstract

Related Concept Videos

In Vitro Drug Dissolution: Compendial Testing Models I01:13

In Vitro Drug Dissolution: Compendial Testing Models I

Compendial dissolution methods are standardized procedures defined by pharmacopeias to evaluate the rate at which a drug dissolves in a specific medium. These methods ensure batch-to-batch consistency, enable quality control, and support the prediction of drug bioavailability. They are critical for both immediate and modified-release drug products.The apparatuses used for dissolution testing differ in their design and mechanical function, but all aim to simulate the physiological environment of...
440
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
647
In Vitro Drug Dissolution: Compendial Testing Models II01:09

In Vitro Drug Dissolution: Compendial Testing Models II

Various dissolution methods are utilized to assess a drug’s dissolution rate, including the flow-through cell, paddle-over-disk, cylinder, and reciprocating disk methods.The flow-through cell apparatus (USP (United States Pharmacopeia) method 4) comprises a reservoir for the dissolution medium and a pump that propels the medium through the cell containing the test sample. This method is crucial for assessing modified-release dosage forms with minimally soluble active ingredients,...
482
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
212
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
397
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
426